Vaccine Design pp 473-493 | Cite as

Water-Soluble Phosphazene Polymers for Parenteral and Mucosal Vaccine Delivery

  • Lendon G. Payne
  • Sharon A. Jenkins
  • Alexander Andrianov
  • Bryan E. Roberts
Part of the Pharmaceutical Biotechnology book series (PBIO, volume 6)

Abstract

The advent of modern molecular biology has provided us with a means of producing antigens with unprecedented ease and precision. It is ironic that these new methodologies generate purified antigens that do not generally induce a strong immune response in the absence of an effective adjuvant. The development of improved vaccine adjuvants for use in humans has therefore become a priority area of research. Nevertheless, research on adjuvants has lagged seriously behind the work done on antigens. For decades the only adjuvant widely used in humans has been alum. Saponin and its purified component Quil A, complete Freund’s adjuvant (CFA) and other adjuvants used in research and veterinary applications have toxicities that limit their potential use in human vaccines. New chemically defined preparations such as QS-21, muramyl dipeptide, and monophosphoryl lipid A are being studied.

Keywords

Permeability Surfactant Toxicity Electrophoresis Lysine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Allcock, H. R., and Kwon, S., 1989, An ionically cross-linkable polyphosphazene: Polyt[bis(carboxylatophenoxy)phosphazene] and its hydrogels and membranes, Macromolecules 22:75–79.CrossRefGoogle Scholar
  2. Allison, A. C., and Byars, N. E., 1992, Immunological adjuvants and their mode of action, in Vaccines: New Approaches to Immunological Problems (R. W. Ellis, ed.), Butterworth-Heinemann, Oxford, pp. 431–448.Google Scholar
  3. Andrianov, A. K., Cohen, S., Visscher, K. B., Payne, L. G., Allcock, H. R., and Langer, R., 1993a, Controlled release using ionotropic polyphosphazene hydrogels, J. Controlled Rel. 27:69–77.CrossRefGoogle Scholar
  4. Andrianov, A. K., Payne, L. G., Visscher, K. B., Allcock, H. R., and Langer, R., 1993b, Hydrolytic degradation of polyphosphazene hydrogels, Polym. Prepr. 34:233–234.Google Scholar
  5. Andrianov, A. K., Payne, L. G., Visscher, K. B., Allcock, H. R., and Langer, R., 1994, Hydrolytic degradation of ionically cross-linked polyphosphazene microspheres, J. Appl. Polym. Sci. 53:1573–1578.CrossRefGoogle Scholar
  6. Bano, M. C., Cohen, S., Visscher, K. B., Allcock, H. R., and Langer, R., 1991, A novel synthetic method for hybridoma cell encapsulation, Bio/Technol. 9:468–471.CrossRefGoogle Scholar
  7. Cohen, S., Bano, M. C., Visscher, K. B., Chow, M., Allcock, H. R., and Langer, R., 1990, Ionically cross-linkable polyphosphazene: A novel polymer for microencapsulation, J. Am. Chem. Soc. 112:7832–7833.CrossRefGoogle Scholar
  8. Eidridge, J. H., Gilley, R. M., Staas, J. K., Moldoveanu, Z., Meulbroek, J. A., and Tice, T. R., 1989, Biodegradable microspheres: Vaccine delivery system for oral immunization, Curr. Top. Microbiol. Immunol. 146:59–66.CrossRefGoogle Scholar
  9. Eidridge, J. H., Staas, J. K., Meulbroek, J. A., Tice, T. R., and Gilley, R. M., 1991, Biodegradable and biocompatible poly(DL-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies, Infect. Immun. 59:2978–2986.Google Scholar
  10. Gray, D., 1993, Immunological memory, Annu. Rev. Immunol. 11:49–77.PubMedCrossRefGoogle Scholar
  11. Hunter, R. L., 1991, Nonionic block copolymers: New preparations and review of the mechanism of action, in: Topics in Vaccine Adjuvant Research (D. R. Spriggs and W. C. Koff, eds.), CRC Press, Boca Raton, pp. 89–97.Google Scholar
  12. Kreuter, J., 1992, Microcapsules and nanoparticles, in: Medicine and Pharmacology (M. Donbrow, ed.), CRC Press, Boca Raton, pp. 125–148.Google Scholar
  13. Payne, L. G., Jenkins, S. A., Andrianov, A., Langer, R., and Roberts, B. E., 1995, Xenobiotic polymers as vaccine vehicles, Adv. Exp. Med. Biol. (in press).Google Scholar
  14. Petrov, R., Mustafaev, M., and Norimov, A., 1992, Physico-chemical criteria for the construction of artificial immunomodulators and immunogens on the basis of polyelectrolyte complexes, Sov. Med. Rev. Sect. D Immunol. 4:1–113.Google Scholar
  15. White, R. G., 1976, Adjuvant effect of microbial products in the immune response, Annu. Rev. Microbiol. 30:579–600.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1995

Authors and Affiliations

  • Lendon G. Payne
    • 1
  • Sharon A. Jenkins
    • 1
  • Alexander Andrianov
    • 1
  • Bryan E. Roberts
    • 1
  1. 1.Virus Research Institute, Inc.CambridgeUSA

Personalised recommendations